O'Melveny
We only have limited information for this firm. Consider the following firms which have provided more information:
O'Melveny specialises in bringing life sciences and biotech companies in China to the public markets in Hong Kong and the United States, assisting them with capital markets, M&A, FDI, IP, licensing, private equity and venture capital transactions. The firm acts for clients in this sector from across China’s major cities, including Beijing, Shanghai and Nanjing. Practice head Ke Geng is an expert advisor on biotech and medical device IPOs, who also has direct industry knowledge through holding a biochemistry PhD.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
‘Significant and long-term industry experience in the field of life sciences and healthcare capital markets. The team is stable and provides continuous legal support to clients.’
‘Ke Geng is professional, efficient and experienced.'
Abbreviated data is displayed for this firm.
Key clients
- Luzhu Biotech
- Acotec Scientific Holdings
Abbreviated data is displayed for this firm.
Work highlights
- Advised Luzhu Biotech on its Hong Kong IPO.
- Advised Acotec Scientific Holdings Limited on a voluntary partial offer by Boston Scientific Group plc.
Abbreviated data is displayed for this firm.